Hoffmann-La Roche Inc.

Engmab Sarl

Engmab Ag

F. Hoffmann-La Roche Ag

Engmab Beta Holdings LLC

Lydia Jasmin Hanisch

Christian Klein

Ekkehard Moessner

Wei Xu

Pablo Umana

Stefan Klostermann

Samuel Moser

Wolfgang Schaefer

Ralf Hosse

Pablo Umaña

Alexander Bujotzek

Christian Jost

Camille Loise Sophie Delon

Vesna Pulko

Guy Georges

Thomas U Hofer

Marina Bacac

Anne Freimoser-Grundschober

Werner Scheuer

Oliver Ast

Juergen Michael Schanzer

Joerg Benz

Claudio Sustmann

Tina Weinzierl

Tanja Fauti

Klaus Strein

Minh Diem Vu

Johannes Sam

Diana Darowski

Rebecca Croasdale-Wood

Joerg Thomas Regula

Michael Molhoj

Ramona Murr

Sabine Jung-Imhof

Estelle Marrer-Berger

Camille Delon

Simon Patrick Keiser

Alejandro Carpy Gutierrez Cirlos

Anne Freimoser-grundschober

The present invention generally relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to HLA-A2/WT1

The present invention generally relates to diagnostic assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter cell assays to analyze samples, in particular patient samples, to diagnose cancer by quantifying the expression of tumor antigens and/or predicting clinical response to cancer immunotherapies. A further aspect of the present invention is to improve safety of e.g., cancer immunotherapies.

CAR-T reporter based diagnostic assays to detect tumor antigens in cancer patients

The present invention generally relates to specificity assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter T (CAR-T) cell assays to test novel antigen binding moieties in different formats. Furthermore, the present invention relates to the use of CAR-T cells, transfected/transduced with an engineered chimeric antigen receptor (CAR) comprising a target antigen binding moiety capable of specific binding to a recognition domain of an antigen binding molecule. The invention also relates to methods and kits for specificity testing of a candidate antigen binding moiety and/or nucleic acid molecules and vectors expressing engineered CARs.

Universal reporter cell assay for specificity test of novel antigen binding moieties

The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to HLA-A2/MAGE-A4

The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific HER2 antibodies and methods of use

The present invention generally relates to specificity assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter T (CAR-T cell) assays to test antigen binding moieties in different formats. Furthermore, the present invention relates to the use of CAR-T cells, transfected/transduced with an engineered chimeric antigen receptor (CAR) comprising a target antigen binding moiety capable of specific binding to a target antigen, e.g., tumor associated antigens.

Car-t cell assay for specificity test of novel antigen binding moieties

The invention relates to new antibodies against BCMA, their manufacture and use.

Monoclonal antibodies against BCMA

A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3&#x3b5;, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.

Bispecific antibodies against CD3&#x3f5; and BCMA

Growing community of inventors

Birmensdorf, Switzerland

Lydia Jasmin Hanisch